News
Vincerx Pharma
VINC · NASDAQ
$0.015+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.015
Latest news
- NewsRishabh Mishra
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earnings
- NewsRishabh Mishra
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
- Press releaseGlobe Newswire
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
- NewsRishabh Mishra
US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert
- Press releaseGlobe Newswire
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258
- NewsAvi Kapoor
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders
- Press releaseBusiness Wire
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders
- Press releaseBusiness Wire
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
- Press releaseBusiness Wire
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- Press releaseGlobe Newswire
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
- NewsVandana Singh
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
- Press releaseGlobe Newswire
Vincerx Pharma Reports Second Quarter 2024 Financial Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.